MX342138B - Composiciones y metodos para el tratamiento de influenza. - Google Patents

Composiciones y metodos para el tratamiento de influenza.

Info

Publication number
MX342138B
MX342138B MX2012015232A MX2012015232A MX342138B MX 342138 B MX342138 B MX 342138B MX 2012015232 A MX2012015232 A MX 2012015232A MX 2012015232 A MX2012015232 A MX 2012015232A MX 342138 B MX342138 B MX 342138B
Authority
MX
Mexico
Prior art keywords
compositions
methods
treating influenza
influenza
provided compositions
Prior art date
Application number
MX2012015232A
Other languages
English (en)
Other versions
MX2012015232A (es
Inventor
David E Anderson
Andrei Ogrel
Ronald Erwin Boch
Jeff Baxter
Original Assignee
Variation Biotechnologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Variation Biotechnologies Inc filed Critical Variation Biotechnologies Inc
Publication of MX2012015232A publication Critical patent/MX2012015232A/es
Publication of MX342138B publication Critical patent/MX342138B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Abstract

La presente invención se refiere a composiciones y métodos útiles para el tratamiento de influenza. Como se describe en la presente, las composiciones y métodos provistos están basados en el desarrollo de ciertas composiciones que incluyen un antígeno de hemaglutinina de virus de influenza en combinación con vesículas de lípido que incluyen un surfactante no iónico (NISV) y opcionalmente un adyuvante. En ciertas modalidades, las composiciones provistas siguen siendo potentes aun cuando no son almacenadas en un sistema de cadena frío estándar (esto es, son termoestables).
MX2012015232A 2010-07-06 2011-07-06 Composiciones y metodos para el tratamiento de influenza. MX342138B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36189810P 2010-07-06 2010-07-06
US201161431218P 2011-01-10 2011-01-10
PCT/US2011/043094 WO2012006367A2 (en) 2010-07-06 2011-07-06 Compositions and methods for treating influenza

Publications (2)

Publication Number Publication Date
MX2012015232A MX2012015232A (es) 2013-02-26
MX342138B true MX342138B (es) 2016-09-14

Family

ID=45441781

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012015232A MX342138B (es) 2010-07-06 2011-07-06 Composiciones y metodos para el tratamiento de influenza.

Country Status (10)

Country Link
US (1) US9610248B2 (es)
EP (1) EP2590674B1 (es)
JP (1) JP6119030B2 (es)
CN (1) CN103096922B (es)
AU (1) AU2011276223C1 (es)
BR (1) BR112013000394B8 (es)
CA (1) CA2840079C (es)
IL (1) IL224022B (es)
MX (1) MX342138B (es)
WO (1) WO2012006367A2 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9907746B2 (en) 2009-07-06 2018-03-06 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
MX2012000372A (es) * 2009-07-06 2012-02-28 Variation Biotechnologies Inc Metodos para preparar vesiculas y formulaciones producidas a partir de las mismas.
US9610248B2 (en) 2010-07-06 2017-04-04 Variation Biotechnologies, Inc. Compositions and methods for treating influenza
CN103501811B (zh) 2011-01-13 2016-03-30 变异生物技术公司 用于治疗病毒感染的组合物和方法
WO2013072768A2 (en) * 2011-11-18 2013-05-23 Variation Biotechnologies, Inc. Synthetic derivatives of mpl and uses thereof
AU2013208693B2 (en) 2012-01-12 2017-12-07 Variation Biotechnologies Inc. Compositions and methods for treating viral infections
US20150079077A1 (en) 2012-01-27 2015-03-19 Variation Biotechnologies, Inc. Methods and compositions for therapeutic agents
US9149521B2 (en) 2013-09-25 2015-10-06 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9504743B2 (en) 2013-09-25 2016-11-29 Sequoia Sciences, Inc Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9149522B2 (en) 2013-09-25 2015-10-06 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US20150086592A1 (en) * 2013-09-25 2015-03-26 Sequoia Sciences, Inc Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
GB201814959D0 (en) 2018-09-14 2018-10-31 Secr Defence Methods for the preparation of a pharmaceutical-vesicle formulation and associated products and uses

Family Cites Families (128)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4024241A (en) 1974-09-27 1977-05-17 The United States Of America As Represented By The Secretary Of Health, Education And Welfare Nuclease-resistant hydrophilic complex of polyriboinosinic-polyribocytidylic acid
US3952097A (en) 1974-09-27 1976-04-20 The United States Of America As Represented By The Department Of Health, Education And Welfare Nuclease-resistant hydrophilic complex of polyriboinosinic-polyribocytidylic acid
US4349538A (en) 1979-12-07 1982-09-14 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Nuclease-resistant hydrophilic complex of polyriboinosinic-polyribocytidylic acid
JPS56115727A (en) 1980-02-19 1981-09-11 Kuraray Co Ltd Carrier for immobilizing physiologically active substance
US4537769A (en) * 1982-04-06 1985-08-27 American Cyanamid Company Stabilization of influenza virus vaccine
US4894228A (en) 1982-04-07 1990-01-16 The United States Of America As Represented By The Department Of Health And Human Services Vaccine against hepatitis A virus
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US4983387A (en) 1986-05-19 1991-01-08 Viral Technologies Inc. HIV related peptides, immunogenic antigens, and use therefor as subunit vaccine for AIDS virus
WO1988006882A1 (en) 1987-03-13 1988-09-22 Micro Vesicular Systems, Inc. Lipid vesicles formed of surfactants and steroids
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US5160669A (en) 1988-03-03 1992-11-03 Micro Vesicular Systems, Inc. Method of making oil filled paucilamellar lipid vesicles
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US4911517A (en) 1988-09-09 1990-03-27 Square D Company Means for clamping fiber optical cable
US5549910A (en) 1989-03-31 1996-08-27 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
US5817318A (en) 1989-05-03 1998-10-06 Connaught Laboratories Limited Synthetic peptides for an HIV-1 vaccine
CN1022331C (zh) 1989-08-17 1993-10-06 浙江省医学科学院 甲型肝炎减毒活疫苗毒种及其制造方法
DE3934366A1 (de) 1989-10-14 1991-04-18 Chemotherapeutisches Forschungsinstitut Georg Speyer Haus Vakzine zum schutz vor hiv-virusinfektionen, verfahren zu ihrer herstellung und ihre verwendung als diagnostikum und immuntherapeutikum
IE904098A1 (en) 1989-11-13 1991-05-22 Nova Pharm Corp Lipospheres for controlled delivery of substances
JP2502234B2 (ja) 1990-06-29 1996-05-29 カイロン コーポレイション リポソ―ム含有ワクチン組成物
US5250236A (en) 1991-08-05 1993-10-05 Gasco Maria R Method for producing solid lipid microspheres having a narrow size distribution
GB9207731D0 (en) 1992-04-07 1992-05-27 Proteus Molecular Design Improvements in or relating to vaccines
ES2107668T3 (es) 1992-07-08 1997-12-01 Dianorm G Maierhofer Gmbh Liposomas, procedimiento para su preparacion y su uso en la elaboracion de un medicamento.
JP3523646B2 (ja) 1992-09-18 2004-04-26 スミスクライン・ビーチヤム・バイオロジカルズ・エス・エイ Ａ型肝炎ワクチン
US5393527A (en) 1993-01-04 1995-02-28 Becton, Dickinson And Company Stabilized microspheres and methods of preparation
ES2145132T3 (es) 1993-02-26 2000-07-01 Fountain Pharm Inc Sistema de suministro de vacunas y solucion precursora estable en almacenamiento para la encapsulacion a distancia de ingredientes activos.
US5885486A (en) 1993-03-05 1999-03-23 Pharmaciaand Upjohn Ab Solid lipid particles, particles of bioactive agents and methods for the manufacture and use thereof
JPH08512056A (ja) 1993-06-30 1996-12-17 ジェネンテク・インコーポレイテッド リポソームの製造法
US5762939A (en) 1993-09-13 1998-06-09 Mg-Pmc, Llc Method for producing influenza hemagglutinin multivalent vaccines using baculovirus
GB9320597D0 (en) 1993-10-06 1993-11-24 Proteus Molecular Design Improvements in and realting to vaccines
RU2154068C2 (ru) 1993-11-17 2000-08-10 Лаборатуар Ом С.А. Глюкозаминовые дисахариды, способ их получения, фармацевтическая композиция
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
CA2180965C (en) 1994-01-11 2010-05-11 Tom Maria Deroo Influenza vaccine
US5824536A (en) 1994-08-23 1998-10-20 St. Jude Children's Research Hospital Influenza virus replicated in mammalian cell culture and vaccine production
US6235888B1 (en) 1994-10-05 2001-05-22 The General Hospital Corporation Hepatitis C virus vaccine
GB9515868D0 (en) 1995-08-02 1995-10-04 Proteus Molecular Design Therapeutic method
GB9522351D0 (en) 1995-11-01 1996-01-03 Medeva Holdings Bv Vaccine compositions
US5700679A (en) 1996-06-07 1997-12-23 Novavax, Inc. Lipid vesicles having a bilayer containing a surfactant with anti-viral and spermicidal activity
US5919480A (en) * 1996-06-24 1999-07-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem Liposomal influenza vaccine composition and method
ES2242226T3 (es) 1996-07-03 2005-11-01 Eisai Co., Ltd. Composiciones que contienen analogos del lipido a y procedimiento parasu preparacion.
ZA975889B (en) 1996-07-08 1998-02-23 Genentech Inc HIV envelope polypeptides and vaccine.
EP0938298B1 (en) 1996-09-13 2002-12-04 Lipoxen Technologies Limited Liposome-based composition
US5910306A (en) 1996-11-14 1999-06-08 The United States Of America As Represented By The Secretary Of The Army Transdermal delivery system for antigen
US6290967B1 (en) 1996-12-20 2001-09-18 Merck & Co., Inc. Stabilizers for lyophilized vaccines
FR2760367B1 (fr) 1997-03-06 1999-04-30 Pasteur Merieux Serums Vacc Composition vaccinale destinee a la prevention ou au traitement des hepatites c
TW570803B (en) 1997-04-09 2004-01-11 Duphar Int Res Influenza vaccine
US6303347B1 (en) 1997-05-08 2001-10-16 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US6764840B2 (en) 1997-05-08 2004-07-20 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US5977081A (en) 1997-05-20 1999-11-02 Galenica Pharmaceuticals, Inc. Triterpene saponin analogs having adjuvant and immunostimulatory activity
US6080725A (en) 1997-05-20 2000-06-27 Galenica Pharmaceuticals, Inc. Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof
GB9725084D0 (en) 1997-11-28 1998-01-28 Medeva Europ Ltd Vaccine compositions
US6503753B1 (en) 1998-02-13 2003-01-07 Adan Rios Method for the development of an HIV vaccine
AU764938B2 (en) 1998-02-13 2003-09-04 Adan Rios Method for the development of an HIV vaccine
EP1078105B1 (en) 1998-05-12 2004-11-24 Genecure LLC Replication defective hiv vaccine
US7067134B1 (en) 1998-08-12 2006-06-27 University Of Western Ontario HIV vaccine
AT408615B (de) 1998-09-15 2002-01-25 Immuno Ag Neue influenzavirus-impfstoffzusammensetzung
GB9822714D0 (en) 1998-10-16 1998-12-09 Smithkline Beecham Sa Vaccines
US6287570B1 (en) 1998-11-23 2001-09-11 Patricia L. Foley Vaccine against swine influenza virus
GB9826069D0 (en) 1998-11-28 1999-01-20 Univ Leeds HIV vaccine
IL127331A0 (en) 1998-11-30 1999-09-22 Yeda Res & Dev Peptide-based vaccine for influenza
US6551600B2 (en) 1999-02-01 2003-04-22 Eisai Co., Ltd. Immunological adjuvant compounds compositions and methods of use thereof
US20040006242A1 (en) 1999-02-01 2004-01-08 Hawkins Lynn D. Immunomodulatory compounds and method of use thereof
AT407958B (de) 1999-02-11 2001-07-25 Immuno Ag Inaktivierte influenza-virus-vakzine zur nasalen oder oralen applikation
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
NO311807B1 (no) 1999-03-04 2002-01-28 Bionor Immuno As HIV-peptider, antigener, vaksinepreparater, immunoassay- testsett og en metode for påvisning av antistoffer fremkalt av HIV
WO2001002607A1 (en) 1999-07-06 2001-01-11 Merck & Co., Inc. Adenovirus carrying gag gene hiv vaccine
AU5905400A (en) 1999-07-14 2001-02-05 Board Of Regents, The University Of Texas System Methods and compositions for delivery and retention of active agents to lymph nodes
JP5388395B2 (ja) 1999-07-15 2014-01-15 ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア 脂質に被包された治療剤の製造方法
JP2003526339A (ja) 1999-07-28 2003-09-09 スミス、スチーブン 条件付きの制御がなされた弱毒ｈｉｖワクチン
BR0014281A (pt) 1999-09-24 2002-05-21 Smithkline Beecham Biolog Vacina contra vìrus de gripe intranasal
ES2267724T3 (es) 2000-02-15 2007-03-16 Id Biomedical Corporation Of Quebec Vacuna antigripal basada en proteosomas.
FR2806912B1 (fr) 2000-04-04 2004-07-23 Fond Mondiale Rech Et Preventi UTILISATION DE PROTEINES gp120 ET gp160 MODIFIEES DANS LA BOUCLE V3 DU VIH-1 POUR LA PREPARATION DE COMPOSITIONS VACCINALES ET FORMULATIONS LES CONTENANT
US20030092145A1 (en) 2000-08-24 2003-05-15 Vic Jira Viral vaccine composition, process, and methods of use
AU2356002A (en) 2000-09-25 2002-04-02 Polymun Scient Immunbio Forsch Live vaccine and method of manufacture
ES2291379T3 (es) 2000-12-27 2008-03-01 Ares Trading S.A. Nanoparticulas lipidicas anfifilicas para la incorporacion de peptidos y/o proteinas.
MY134424A (en) 2001-05-30 2007-12-31 Saechsisches Serumwerk Stable influenza virus preparations with low or no amount of thiomersal
US7361352B2 (en) 2001-08-15 2008-04-22 Acambis, Inc. Influenza immunogen and vaccine
CA2472579A1 (en) 2002-01-14 2003-07-24 Chiron Corporation Hiv vaccine and method of use
US7285289B2 (en) 2002-04-12 2007-10-23 Nagy Jon O Nanoparticle vaccines
US20050169979A1 (en) 2002-07-03 2005-08-04 Dov Michaeli Liposomal vaccine
ATE348633T1 (de) 2002-07-05 2007-01-15 Lipoxen Technologies Ltd Verfahren zur verstärkung einer immunantwort von nukleinsäureimpfungen
US20040011840A1 (en) 2002-07-22 2004-01-22 Lovett Terry E. Rolling motorcycle bag
EP2481819A1 (en) 2003-02-25 2012-08-01 MedImmune Vaccines, Inc. Cross flow filtration in the production of stabilized influenza vaccine compositions
EP1618127B1 (en) 2003-04-10 2014-12-10 Novartis Vaccines and Diagnostics, Inc. Immunogenic composition comprising a spike protein of the SARS coronavirus
AU2004263816A1 (en) 2003-05-15 2005-02-17 The Board Of Regents For Oklahoma State University DNA vaccine expressing HA1 of equine-2 influenza virus
BRPI0411505A (pt) 2003-06-18 2006-07-25 Yissum Res Dev Co uso de um composto, método para modular a resposta imune de um indivìduo, composição farmacêutica, vacina, complexo, e, kit para a captura de uma molécula biologicamente ativa
US7368537B2 (en) 2003-07-15 2008-05-06 Id Biomedical Corporation Of Quebec Subunit vaccine against respiratory syncytial virus infection
GB0321615D0 (en) 2003-09-15 2003-10-15 Glaxo Group Ltd Improvements in vaccination
US20050095283A1 (en) 2003-09-16 2005-05-05 Aphios Corporation Compositions and methods for topically treating diseases
US20080160089A1 (en) 2003-10-14 2008-07-03 Medivas, Llc Vaccine delivery compositions and methods of use
US7498309B2 (en) 2003-11-29 2009-03-03 Sangstat Medical Corporation Pharmaceutical compositions for bioactive peptide agents
AU2005248361B2 (en) 2004-05-18 2010-03-11 Vical Incorporated Influenza virus vaccine composition and methods of use
US7527800B2 (en) 2004-05-25 2009-05-05 Medimmune, Llc Influenza hemagglutinin and neuraminidase variants
DE602005025342D1 (de) * 2004-05-28 2011-01-27 Glaxosmithkline Biolog Sa Impfstoffzusammensetzungen mit virosomen und einem saponin-adjuvans
EP1809246B1 (en) 2004-10-08 2008-07-16 Alza Corporation Method of insertion of a lipid-linked moiety into a pre-formed lipid assembly using microwaves
EP1824990B1 (en) 2004-12-08 2015-02-18 MedImmune, LLC Methods of producing influenza vaccine compositions
EP1676569A1 (en) 2004-12-30 2006-07-05 Pevion Biotech Ltd. Lyophilization of virosomes
US8029797B2 (en) 2005-03-01 2011-10-04 Variation Biotechnologies Inc. Multivalent HIV immunogenic compositions comprising a pool of lipidated and nonlipidated peptides representing Gag and Env variable regions
US20090028903A1 (en) 2005-03-23 2009-01-29 Glaxosmithkline Biologicals, S.A. Novel use
US7348011B2 (en) 2005-06-10 2008-03-25 Sudershan Biotech Ltd. Hepatitis C virus vaccine
CA2612005C (en) 2005-06-17 2013-10-29 Georgia Tech Research Corporation Coated microstructures and method of manufacture thereof
EP1957647B1 (en) 2005-11-25 2015-03-04 Zoetis Belgium S.A. Immunostimulatory oligoribonucleotides
CA2636424A1 (en) 2006-01-09 2007-10-25 The Regents Of The University Of California Immunostimulatory combinations of tnfrsf, tlr, nlr, rhr, purinergic receptor, and cytokine receptor agonists for vaccines and tumor immunotherapy
WO2007098186A2 (en) 2006-02-22 2007-08-30 Novavax, Inc. Adjuvant and vaccine compositions
US8846078B2 (en) 2006-03-21 2014-09-30 The Secretary Of State For Environment, Food & Rural Affairs Acting Through The Animal Health And Veterinary Laboratories Agency Brucellosis DNA vaccine
JP2009534303A (ja) * 2006-03-24 2009-09-24 ノバルティス ヴァクシンズ アンド ダイアグノスティクス ゲーエムベーハー アンド カンパニー カーゲー 冷蔵しないインフルエンザワクチンの保存
JP2010502822A (ja) 2006-09-05 2010-01-28 メディバス エルエルシー ポリマー安定化リポソーム組成物および使用方法
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
SI2068918T1 (sl) * 2006-09-26 2012-09-28 Infectious Disease Res Inst Si - ep sestavek za cepljenje, ki vsebuje sintetiäśna pomagala
AU2008222523A1 (en) 2007-03-07 2008-09-12 Nventa Biopharmaceuticals Corporation Double-stranded locked nucleic acid compositions
ES2542058T3 (es) 2007-03-30 2015-07-30 Particle Sciences, Inc. Formulaciones en forma de partículas y usos de las mismas
EP2014279A1 (en) * 2007-06-22 2009-01-14 Pevion Biotech AG Virosomes comprising hemagglutinin derived from an influenza virus produced in a cell line, compositions, methods of manufacturing, use thereof
EP2192917B1 (en) 2007-08-28 2014-01-29 Baxter International Inc. Method for producing viral vaccines
US20110105995A1 (en) * 2008-01-16 2011-05-05 Zhu Ting F Uniform-sized, multi-drug carrying, and photosensitive liposomes for advanced drug delivery
CA2735724C (en) * 2008-06-19 2018-07-24 Variation Biotechnologies Inc. Compositions and methods for treating influenza
WO2010033812A1 (en) 2008-09-18 2010-03-25 Variation Biotechnologies, Inc. Compositions and methods for treating hepatitis a.
US8343497B2 (en) 2008-10-12 2013-01-01 The Brigham And Women's Hospital, Inc. Targeting of antigen presenting cells with immunonanotherapeutics
US9907746B2 (en) 2009-07-06 2018-03-06 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
MX2012000372A (es) 2009-07-06 2012-02-28 Variation Biotechnologies Inc Metodos para preparar vesiculas y formulaciones producidas a partir de las mismas.
US9610248B2 (en) 2010-07-06 2017-04-04 Variation Biotechnologies, Inc. Compositions and methods for treating influenza
WO2012006368A2 (en) 2010-07-06 2012-01-12 Variation Biotechnologies, Inc. Compositions and methods for treating influenza
CN103501811B (zh) 2011-01-13 2016-03-30 变异生物技术公司 用于治疗病毒感染的组合物和方法
AU2012205315B2 (en) 2011-01-13 2017-05-04 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
EA201892619A1 (ru) * 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
AU2013208693B2 (en) 2012-01-12 2017-12-07 Variation Biotechnologies Inc. Compositions and methods for treating viral infections
US20150079077A1 (en) 2012-01-27 2015-03-19 Variation Biotechnologies, Inc. Methods and compositions for therapeutic agents

Also Published As

Publication number Publication date
EP2590674A4 (en) 2014-09-10
WO2012006367A3 (en) 2013-04-11
CA2840079A1 (en) 2012-01-12
CA2840079C (en) 2018-07-03
US20130108692A1 (en) 2013-05-02
EP2590674B1 (en) 2017-02-22
BR112013000394B8 (pt) 2022-01-18
AU2011276223B2 (en) 2015-10-22
JP2013533259A (ja) 2013-08-22
CN103096922A (zh) 2013-05-08
US9610248B2 (en) 2017-04-04
WO2012006367A2 (en) 2012-01-12
EP2590674A2 (en) 2013-05-15
BR112013000394A2 (pt) 2016-06-07
CN103096922B (zh) 2019-08-06
AU2011276223A1 (en) 2013-02-21
AU2011276223C1 (en) 2016-05-12
MX2012015232A (es) 2013-02-26
IL224022B (en) 2019-09-26
BR112013000394B1 (pt) 2021-12-14
JP6119030B2 (ja) 2017-04-26

Similar Documents

Publication Publication Date Title
MX342138B (es) Composiciones y metodos para el tratamiento de influenza.
MX2021006342A (es) Mutantes de virus de influenza y usos para los mismos.
MX2010008799A (es) Proceso para estabilizar una composicion de vacuna que contiene adyuvante.
MX2013013111A (es) Composicion inmunogenica que presenta antigeno multiple, y metodos y usos de la misma.
GB201009273D0 (en) Novel vaccine
MX2014003308A (es) Vacunas para el virus de la influenza y usos de las mismas.
WO2011103453A3 (en) Vaccines for use in the prophylaxis and treatment of influenza virus disease
MX349119B (es) Vacuna de virus de dengue inactivado.
WO2012006368A3 (en) Compositions and methods for treating influenza
BR112015012841A2 (pt) composição imunogênica, vacina, e, uso de uma composição imunogênica
WO2009155489A3 (en) Compositions and methods for treating influenza
CL2012000401A1 (es) Metodo para hacer una composicion para producir un recubrimiento ultrahidrofobo que comprende combinar un primer solvente y las particulas las cuales no son solubles pero dispersables en primer solvente y combinar con segundo solvente, obtener composicion y recuperacion de la composicion; recubrimiento ultrahidrofobo; y composicion.
PH12015501101B1 (en) Method for eliciting an immune response to an immunogen
ECSP13013093A (es) Composiciones líquidas de limpieza de sal
MX2012009046A (es) Composiciones y metodos de inmunizacion.
WO2012121547A3 (ko) 웨이퍼 가공 필름용 점착제 조성물
MX359103B (es) Composiciones y sus usos en el tratamiento de infecciones virales.
MX2015013832A (es) Composicion de vacuna y metodo de uso.
ECSP13013094A (es) Composiciones de limpieza de sal colina
WO2013111012A3 (en) Methods and compositions for therapeutic agents
MX366051B (es) Composiciones del virus del síndrome reproductor y respiratorio de porcino y sus usos.
PH12015501335A1 (en) Immunogenic composition comprising mycoplasma antigens
MX2019013641A (es) Antigenos de pertussis acelulares no entrelazados para uso en vacunas de combinacion.
MX350718B (es) Vacuna de rinitis equina.
BR112015012515A2 (pt) métodos para a indução de anticorpos

Legal Events

Date Code Title Description
FG Grant or registration